Considering that PD‐L1 is overexpressed in BCG‐unresponsive tumors and is associated with BC stage progression,47 several anti‐PD‐L1 and antiprogrammed cell death protein 1 (PD‐1) drugs are being tested in patients with NMIBC who are refractory to BCG, or in patients with very high‐risk NMIBC and unexposed to BCG. Here, PDCD1 is linked to breast cancer.